An observational study in Healthy Subjects, Chronic Obstructive Pulmonary Disease and Asthma, sponsored by Guangzhou Institute of Respiratory Disease. Status unknown at 2 sites in China. Open to participants aged 4 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-16.
Sponsored by Guangzhou Institute of Respiratory Disease · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Pulmonary Disease, Chronic Obstructive by Guangzhou Institute of Respiratory Disease — 2 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Guangzhou Institute of Respiratory Disease.
Among the 22 studies in Pulmonary Disease, Chronic Obstructive by Guangzhou Institute of Respiratory Disease, this one is one of 6 that started in 2016, is one of 7 observational ones, and was the 11th registered.
5,521 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 22 studies in Pulmonary Disease, Chronic Obstructive by Guangzhou Institute of Respiratory Disease are open now, in 1 country. Recruiting first, the newest first:
Guangzhou Institute of Respiratory Disease · Sites in China
Ages 18+
Guangzhou Institute of Respiratory Disease
Ages 35+ · Healthy volunteers
By country, each count listing its studies:
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 4 Years to 95 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,000 is above the median of 158 across 1,497 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 18 across the 15 interventional studies, 400 across the 7 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Guangzhou Institute of Respiratory Disease is the lead sponsor of 99 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Pulmonary Disease, Chronic Obstructive by Guangzhou Institute of Respiratory Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the reference values of impulse oscillometry (IOS) in healthy Chinese, and compare the indices of IOS in patients with lung disease, such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), and upper airway Obstruction (UAO).
Subjects will be recruited from outpatient clinics.
Inclusion Criteria for healthy subjects:
Inclusion Criteria for :
Inclusion Criteria for asthma:
Inclusion Criteria for ILD:
Inclusion Criteria for UAO:
Exclusion Criteria for healthy subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects.
Other: Clinical Observation
Patience with chronic obstructive pulmonary disease.
Other: Clinical Observation
Patience with asthma.
Other: Clinical Observation
Patience with interstitial lung disease.
Other: Clinical Observation
Patience with upper airway obstruction.
Other: Clinical Observation
No treatment given but observation with IOS
Airway resistance
The indices of Airway resistance include total respiratory impedance (Zrs).
Time frame: one minute
forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, and maximum midexpiratory flow (MMEF).
The indices of spirometry include forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, and maximum midexpiratory flow (MMEF).
Time frame: one minute
The record gives a start of Sep 2016, a primary completion of Jun 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Guangzhou Institute of Respiratory Disease